# US 2005/0087719 A1 · Magnetic nanodispersion with cyclodextrines and method for the production thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0087719 A1
- Document ID: US20050087719A1
- Status: Published application
- Kind: A1
- Application number: 10/493,954
- Filed: 2002-10-28
- Published: 2005-04-28
- Earliest claimed: 2001-10-26
- Inventors: Christian Gansau; Norbert Buske; Thomas Gotze
- Web page: https://patentgrep.com/patent/US20050087719A1

## CPC

- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- A61K 49/1863: {the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch}
- A61K 49/189: {Host-guest complexes, e.g. cyclodextrins}
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- Y10T 428/2991: Coated
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

Substituted and non-substituted cyclodextrines are used as stabilizing agents for nanodispersions containing magnetic core particles M. The nanodispersions, which exhibit high saturation polarization with great biocompatibility, are suitable as transport vehicles for other pharmacologically and biologically active substances. The magnetic core particles of the nanodispersions are enveloped by compounds of the general formula (Ap, C, Bq), wherein A is reactive groups, B is bioactive groups and C is cyclodextrines.

## Claims

### Claim 1

Magnetic dispersion based on water, or dispersants which can be mixed with water, and magnetic nanoparticles dispersed and stabilised therein, wherein the magnetic nanoparticles consist essentially of magnetic core particles and a shell of the general formula
M[Ap, C, Bq]
wherein
M is magnetic core particles,
A is reactive groups,
B is bioactive groups and
C is cyclodextrines,
consisting of
1,4-linked glucose units (C6H7O5)m[(3H)m-(p+q)],
wherein
m=6 to 12,
p is the number of A groups 1 to 3m and
q is the number of B groups 3m-p.

### Claim 2 (depends on 1)

Magnetic dispersion according to claim 1, wherein the reactive A groups are —H and/or —(CH2)n—R and their salts,
wherein
n may assume the values from 0 to 20 and
R is —H, —(OH), —CHOH—CH3, —(COOH), —(NH2), —(SH), —(C3N3ClONa), —(OC2H4NH2), —(NCH3(CHO)), —(ONO2), —(OSO3H), —(OPO3H2), —(COC6H5), —(OCOR′), —(OCO(CH2)n—COOH), —(OCH3), —(OCH2CO2Na), —(O(CH2)nR′), —(OCH2CHOHCH2OH), —(O(CH2CH2O)nR′), —(O(CH2)nSO3H), wherein R′ is —H, —(OH), —(COOH), —(NH2), —(SH), —(ONO2), —(OSO3H), —(OPO3H2).

### Claim 3 (depends on 1, 2)

Magnetic dispersion according to claim 1 or 2, wherein the number q of bioactive B groups is zero.

### Claim 4 (depends on 3)

Magnetic dispersion according to claim 3, wherein only so many A groups are substituted as are necessary for binding to the core particles M.

### Claim 5 (depends on 4)

Magnetic dispersion according to claim 4, wherein the degree of substitution is between 0 and 3 per glucose molecule.

### Claim 6 (depends on 1, 2)

Magnetic dispersion according to claim 1 or 2, wherein the bioactive B groups are derived from one or more of avidins, insulin, heparin, nucleic acids, antibodies, oligopeptides, amino acid and enzymes.

### Claim 7 (depends on 1, 2)

Magnetic dispersion according to claim 1 or 2, wherein the reactive B groups correspond to those of reactive A groups.

### Claim 8 (depends on 7)

Magnetic dispersion according to claim 7, wherein the A groups, which project into the solution and are not fixed to the core particles M, are modified by coupling chemical or biochemical compounds to form bioactive B groups.

### Claim 9 (depends on 1, 2)

Magnetic dispersion according to claim 1 or 2 wherein the shell has a secondary structure consisting essentially of several cyclodextrin molecules of the general formula [Ap, C, Bq]k condensed in orderly manner, wherein k may assume values between 1 and 200.

### Claim 10 (depends on 1, 2)

Magnetic dispersion according to claim 1 or 2 wherein C is unsubstituted and consists essentially of α-cyclodextrines, β-cyclodextrines and γ-cyclodextrines having the defined molecular weights of 975, 1135 and 1297.

### Claim 11 (depends on 1, 2)

Magnetic dispersion according to claim 1 or 2 wherein the core particles M consist essentially of maghemite and ferrites of the formula Me(II)O Fe(III)2O3, wherein Me(II) is a metal ion, such as Fe, Co, Zn or Mn.

### Claim 12 (depends on 1, 2)

Magnetic dispersion according to claim 1 or 2 wherein the size of the core particles M is between 3 and 300 nm.

### Claim 13 (depends on 1, 2)

Magnetic dispersion according to claim 1 or 2 wherein the magnetic dispersion has a saturation polarization of 0.05 to 80 mT.

### Claim 14 (depends on 1, 2)

Magnetic dispersion according to claim 1 or 2 wherein the dispersants are physiological aqueous solutions, dimethylformamide, polyhydric alcohols, glycerin, ethylene glycol and polyethylene glycol or mixtures thereof.

### Claim 15 (depends on 1)

Process for producing magnetic dispersions according to claim 1, comprising the steps of:
co-precipitating iron (III) and metal (II) salts at a pH value in the alkaline range,
washing using a dispersant and adjusting the pH value in the acid range,
adding a compound of the general formula (Ap, C, Bq) at temperatures between 20 and 90° C.,
wherein
A is reactive groups,
B is bioactive groups and
C is cyclodextrines,
consisting of
1,4-linked glucose units (C6H7O5)m[(3H)m-(p+q)],
wherein
m=6 to 12,
p is the number of A groups 1 to 3m and
q is the number of B groups 3m-p, to form a reaction product,
washing the reaction product using water, and
dispersing the reaction product at temperatures between 20 and 90° C., until a magnetic dispersion is produced.

### Claim 16 (depends on 15)

Process according to claim 15, further comprising the step of using compounds of the general formula (Ap, C, Bq), the A groups of which are —H and/or —(CH2)n—R and their salts,
wherein
n may assume the values from 0 to 20 and
R is —H, (OH), —CHOH—CH3, —(COOH), —(NH2), —(SH), —(C3N3ClONa), —(OC2H4NH2), —(NCH3(CHO)), —(ONO2), —(OSO3H), —(OPO3H2), —(OCOC6H5), —(OCOR′), —(OCO(CH2)n—COOH), —(OCH3), —(OCH2CO2Na), —(O(CH2)nR′), —(OCH2CHOHCH2OH), —(O(CH2CH2O)nR′), —(O(CH2)nSO3H),
wherein
R′ is —H, —(OH), —(COOH), —(NH2), —(SH), —(ONO2), —(OSO3H), —(OPO3H2),
and the B groups are derived from at least one of avidins, streptavidin, insulin, heparin, nucleic acids, antibodies, oligopeptides, amino acid and enzymes.

### Claim 17 (depends on 15)

Process according to claim 15 further comprising the step of using a compound of the general formula (Ap, C), the number of reactive A groups of which corresponds to the number of binding sites on the magnetic core particle M.

### Claim 18 (depends on 17)

Process according to claim 17, further comprising the step of reacting the compound of the general formula (Ap, C) with the magnetic core particles M to form a complex, and then reacting the complex M[Ap, C] with Bq.

### Claim 19 (depends on 15)

Process according to claim 15 further comprising the step of reacting a cyclodextrin C with the magnetic core particle M to form a complex, then reacting the complex M[C] with a compound having reactive group A to form a second complex, and finally reacting the second complex M[Ap, C] with a compound having bioactive group Bq to form M[Ap, C, Bq].

### Claim 20 (depends on 15, 16)

Process according to claim 15 or 16, further comprising the step of setting the pH value, after the first washing process, at a pH value between 1 and 6.

### Claim 21 (depends on 15, 16)

Process according to claim 15 or 16, wherein said adding step comprises adding a mixture of compounds of the general formulae (Ap, C, Bq).

### Claim 22 (depends on 15, 16)

Process according to claim 15 or 16, wherein said adding step comprises the steps of adding a first compound of the general formula (Ap, C, Bq) and in a second step, adding a further compound of the general formula (Ap, C, Bq).

### Claim 23 (depends on 15, 16)

Process according to claim 15 or 16, further comprising the step of using for the bioactive group B an active ester selected from 1-ethyl-(3)-(3-diethylaminopropyl)carbodiimide, 1-cyclohexyl-3(2-morpholinoethyl)carbodiimide, N-hydroxysuccinimide and dicyclohexyl carbodiimide.

### Claim 24 (depends on 1)

Process for producing magnetic dispersions according to claim 1, comprising the steps of:
precipitating a hydroxide from a Me(II) salt solution, wherein Me(II) is a divalent metal ion selected from Fe2+, Co2+, Zn2+ and Mn2+,
treating the hydroxide precipitate with an oxidizing agent,
washing the treated precipitate using a dispersant and adjusting the pH value in the acid range,
adding a compound of the general formula (Ap, C, Bg) at temperatures between 20 and 90° C.,
wherein
A is reactive groups.
B is bioactive groups and
C is cyclodextrines.
consisting of
1.4-linked glucose units (C6H7O5)m[(3H)m-(p+q)],
wherein
m=6 to 12,
p is the number of A groups 1 to 3m and
q is the number of B groups 3m-p, to form a reaction product.
washing the reaction product using water, and
dispersing the reaction product at temperatures between 20 and 90° C. until a magnetic dispersion is produced.

### Claim 25 (depends on 24)

Process according to claim 24 wherein the treating step comprises using an oxidizing agent selected from hydrogen peroxide or oxygen.

### Claim 26 (depends on 15, 24)

Process for producing magnetic dispersions according to claims 15 or 24, further comprising the step of treating the reaction product with a compound having pharmacological and/or biological activity.

### Claim 27 (depends on 26)

Process according to claim 26, wherein the treating step further comprises selecting a compound from antibodies, hormones anti-tumour enzymes or anti-tumour proteins.

### Claim 28

Use of substituted and non-substituted cyclodextrines as stabilising agents for dispersions containing magnetic core particles M.

### Claim 29 (depends on 24)

Process according to claim 24, further comprising the step of using compounds of the general formula (Ap, C, Bq), the A groups of which are —H and/or —(CH2)n—R and their salts,
wherein
n may assume the values from 0 to 20 and
R is —H, (OH), —CHOH—CH3, —(COOH), —(NH2), —(SH), —(C3N3ClONa), —(OC2H4N H2), —(NCH3(CHO)), —(ONO2), —(OSO3H), —(OPO3H2), —(OCOC6H5), —(OCOR′), —(OCO(CH2)n—COOH), —(OCH3), —(OCH2CO2Na), —(O(CH2)nR′), —(OCH2CHOHCH2OH), —(O(CH2CH2O)nR′), —(O(CH2)nSO3H),
wherein
R′ is —H, —(OH), —(COOH), —(NH2), —(SH), —(ONO2), —(OSO3H), —(OPO3H2),
and the B groups are derived from at least one of avidins, streptavidin, insulin, heparin, nucleic acids, antibodies, oligopeptides, amino acid and enzymes.

### Claim 30 (depends on 24)

Process according to claim 24 further comprising the step of using a compound of the general formula (Ap, C), the number of reactive A groups of which corresponds to the number of binding sites on the magnetic core particle M.

### Claim 31 (depends on 30)

Process according to claim 30, further comprising the step of reacting the compound of the general formula (Ap, C) with the magnetic core particles M to form a complex, and then reacting the complex M[Ap, C] with Bq.

### Claim 32 (depends on 24)

Process according to claim 24 further comprising the step of reacting a cyclodextrin C with the magnetic core particle M to form a complex, then reacting the complex M[C] with a compound having reactive group A to form a second complex, and finally reacting the second complex M[Ap, C] with a compound having bioactive group Bq to form M[Ap, C, Bq].

### Claim 33 (depends on 24, 29)

Process according to claim 24 or 29 further comprising the step of setting the pH value, after the first washing process, at a pH value between 1 and 6.

### Claim 34 (depends on 24, 29)

Process according to claim 24 or 29 wherein said adding step comprises adding a mixture of compounds of the general formulae (Ap, C, Bq).

### Claim 35 (depends on 24, 29)

Process according to claim 24 or 29 wherein said adding step comprises the steps of adding a first compound of the general formula (Ap, C, Bq) and in a second step, adding a further compound of the general formula (Ap, C, Bq).

### Claim 36 (depends on 24, 29)

Process according to claim 24 or 29 further comprising the step of using for the bioactive group B an active ester selected from 1-ethyl-(3)-(3-diethylaminopropyl)carbodiimide, 1-cyclohexyl-3(2-morpholinoethyl)carbodiimide, N-hydroxysuccinimide and dicyclohexyl carbodiimide.
